LV10184B - Method of preparation of medicine in the form of tablets - Google Patents

Method of preparation of medicine in the form of tablets Download PDF

Info

Publication number
LV10184B
LV10184B LVP-93-513A LV930513A LV10184B LV 10184 B LV10184 B LV 10184B LV 930513 A LV930513 A LV 930513A LV 10184 B LV10184 B LV 10184B
Authority
LV
Latvia
Prior art keywords
cmto
pna
cmecb
water
weight
Prior art date
Application number
LVP-93-513A
Other languages
English (en)
Latvian (lv)
Other versions
LV10184A (lv
Inventor
Peter Lloyd Oren
Werner Max Karl Seidler
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of LV10184A publication Critical patent/LV10184A/xx
Publication of LV10184B publication Critical patent/LV10184B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
LVP-93-513A 1987-02-27 1993-06-08 Method of preparation of medicine in the form of tablets LV10184B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1991587A 1987-02-27 1987-02-27

Publications (2)

Publication Number Publication Date
LV10184A LV10184A (lv) 1994-10-20
LV10184B true LV10184B (en) 1995-04-20

Family

ID=21795732

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-513A LV10184B (en) 1987-02-27 1993-06-08 Method of preparation of medicine in the form of tablets

Country Status (26)

Country Link
EP (1) EP0280571B1 (cs)
JP (1) JPH082793B2 (cs)
KR (1) KR960005140B1 (cs)
CN (1) CN1023765C (cs)
AR (1) AR243376A1 (cs)
AT (1) ATE92309T1 (cs)
AU (1) AU604849B2 (cs)
CA (1) CA1316110C (cs)
CY (1) CY1741A (cs)
DE (2) DE280571T1 (cs)
DK (1) DK175620B1 (cs)
EG (1) EG18523A (cs)
ES (1) ES2044825T3 (cs)
GR (1) GR930300027T1 (cs)
HK (1) HK125793A (cs)
HU (1) HU202747B (cs)
IE (1) IE61419B1 (cs)
IL (1) IL85538A (cs)
LV (1) LV10184B (cs)
MX (1) MX10558A (cs)
NZ (1) NZ223619A (cs)
PH (1) PH24358A (cs)
PT (1) PT86831B (cs)
RU (1) RU1831337C (cs)
UA (1) UA18251A (cs)
ZA (1) ZA881301B (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
AU660147B2 (en) * 1990-05-04 1995-06-15 Perio Products Ltd. Colonic drug delivery system
FR2667242B1 (fr) * 1990-09-28 1994-11-25 Rhone Poulenc Sante Nouvelles formes orales a liberation prolongee avec un temps de latence au niveau stomacal amoindri.
IT1250654B (it) * 1991-07-08 1995-04-21 Farcon Ag Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
JP2864737B2 (ja) * 1993-10-22 1999-03-08 株式会社ツムラ 徐放性製剤用基剤並びに徐放性製剤及び該製剤の製造方法
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DK0906089T3 (da) * 1996-05-13 2003-12-08 Novartis Consumer Health Sa Mundafgivelsessystem
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
EP1066040B1 (en) * 1998-03-03 2003-02-19 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption
KR100296413B1 (ko) * 1998-04-01 2001-11-14 김선진 세파클러함유서방성정제
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
KR100647901B1 (ko) * 1999-07-09 2006-11-17 보령제약 주식회사 세파클러-함유 서방성 약제조성물 및 그의 제조방법
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
CA2393528C (en) 1999-12-28 2009-12-01 Kimberly-Clark Worldwide, Inc. A wiper containing a controlled-release anti-microbial agent
EP1241973B1 (en) 1999-12-28 2007-04-11 Kimberly-Clark Worldwide, Inc. Use-dependent indicator system for absorbent articles
DE60038980D1 (de) 1999-12-28 2008-07-03 Kimberly Clark Co Antimikrobielles wischtuch mit kontrollierter abgabe für harte oberflächen
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
AU2001278673A1 (en) 2000-10-30 2002-05-15 Lupin Limited Rapidly disintegrating sustained release cefuroxime axetil composition
US7910128B2 (en) * 2003-01-03 2011-03-22 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
DE102005019458A1 (de) 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
EP1837020A1 (en) * 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
DE602007012236D1 (de) 2006-04-26 2011-03-10 Supernus Pharmaceuticals Inc Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
WO2008059792A1 (fr) * 2006-11-13 2008-05-22 Kyorin Pharmaceutical Co., Ltd. Procédé de production d'un comprimé à libération prolongée
JPWO2010110436A1 (ja) 2009-03-27 2012-10-04 杏林製薬株式会社 塩基性添加剤を含有するマトリックス型徐放性製剤
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
CN101912373B (zh) * 2010-08-24 2012-01-04 北京京丰制药有限公司 稳定的头孢克洛分散片及其制备方法
WO2015190456A1 (ja) * 2014-06-10 2015-12-17 ライオン株式会社 清酒酵母を含有する錠剤
JP7426685B2 (ja) * 2018-06-14 2024-02-02 株式会社東洋新薬 錠剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ195933A (en) * 1980-01-11 1982-11-23 Boots Co Ltd Sustained-release pharmaceutical compositions in tablet form
JPS6024765B2 (ja) * 1981-11-27 1985-06-14 辰巳化学株式会社 セフアレキシンの持続性製剤の製造方法
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
LU85058A1 (fr) * 1983-10-24 1985-06-19 Pharlyse Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation
US4520009A (en) * 1983-11-28 1985-05-28 Verex Laboratories, Inc. Sustained released aspirin formulation
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
JPS61286330A (ja) * 1985-06-11 1986-12-16 Teijin Ltd 経口徐放性製剤
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法

Also Published As

Publication number Publication date
DK175620B1 (da) 2004-12-27
HU202747B (en) 1991-04-29
EP0280571A2 (en) 1988-08-31
EG18523A (en) 1993-04-30
ZA881301B (en) 1989-10-25
PH24358A (en) 1990-06-13
ATE92309T1 (de) 1993-08-15
DE3882739D1 (de) 1993-09-16
CY1741A (en) 1995-02-17
PT86831A (pt) 1988-03-01
LV10184A (lv) 1994-10-20
DK98088A (da) 1988-08-28
HUT46531A (en) 1988-11-28
JPH082793B2 (ja) 1996-01-17
AR243376A1 (es) 1993-08-31
NZ223619A (en) 1990-10-26
CN1023765C (zh) 1994-02-16
MX10558A (es) 1993-11-01
AU604849B2 (en) 1991-01-03
DK98088D0 (da) 1988-02-25
RU1831337C (ru) 1993-07-30
ES2044825T3 (es) 1994-11-16
HK125793A (en) 1993-11-19
IL85538A (en) 1991-09-16
DE280571T1 (de) 1993-08-12
ES2044825T1 (es) 1994-01-16
IL85538A0 (en) 1988-08-31
KR960005140B1 (ko) 1996-04-22
GR930300027T1 (cs) 1993-05-24
DE3882739T2 (de) 1994-02-17
IE61419B1 (en) 1994-11-02
CN88101062A (zh) 1988-09-07
EP0280571A3 (en) 1989-01-04
EP0280571B1 (en) 1993-08-04
JPS63227519A (ja) 1988-09-21
UA18251A (uk) 1997-12-25
IE880545L (en) 1988-08-27
KR880009639A (ko) 1988-10-04
PT86831B (pt) 1992-05-29
AU1219388A (en) 1988-09-01
CA1316110C (en) 1993-04-13

Similar Documents

Publication Publication Date Title
LV10184B (en) Method of preparation of medicine in the form of tablets
Kahan Sirolimus: a comprehensive review
Flatt et al. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Schröder et al. A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity
IE841423L (en) Antidiabetic composition
RU94043809A (ru) Лекарственная композиция для релизконтроля
CA2170255A1 (en) Pharmaceutical Composition for Immunoenhancement Therapy
CA2138161A1 (en) Glucagon-like peptide and insulinotropin derivatives
JPS61143316A (ja) 安定な錠剤の製造法
SE8009068L (sv) Partiklar av lipoidlosliga substanser, blandningar innefattande sadana partiklar och pa dessa adsorberade biologiskt aktiva substanser liksom even sett for framstellning av sadana blandningar
EP0477968A1 (en) Extract from Ginkgo biloba leaves, in particular for intravenous injection or infusion, a method of preparation of the extract and ampoule preparations containing the extract
CA2157925A1 (en) Treatment of Mycobacterial Diseases by Administration of Bactericidal/Permeability-Increasing Protein Products
CA2351735A1 (en) Engineered cytotoxic ribonuclease
Read et al. Analysis of factors responsible for continuing mortality after paracetamol overdose
CN102552919A (zh) 一种给药组合物及其制备和使用方法
IL107153A (en) Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture
WO1998019670A3 (en) Combination therapy of hepatitis C infections
DE2925009A1 (de) Zubereitung fuer substanzen, verfahren zu deren herstellung und deren verwendung
Tian et al. Gut microbiota and immune checkpoint inhibitors-based immunotherapy
van Gelder et al. A PROSPECTIVE, RANDOMISED STUDY COMPARING FIXED DOSE VS CONCENTRATION CONTROLLED MMF REGIMENS FOR DE NOVO PATIENTS FOLLOWING RENAL TRANSPLANTATION (THE FDCC TRIAL).
CA2740477C (en) Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut
KR20010024231A (ko) 피복형 용량 단위체
Le Meur et al. THERAPEUTIC DRUG MONITORING OF MMF: A RANDOMIZED MULTICENTER STUDY COMPARING CONCENTRATION CONTROLLED VERSUS FIXED DOSE IN KIDNEY TRANSPLANT RECIPIENTS.
Finegold Anaerobic infections
CA2415082A1 (en) Method for formulating healthcare products with enhanced stability